A Laboratory Model for Heroin Abuse Medications - 8
Launched by NEW YORK STATE PSYCHIATRIC INSTITUTE · Sep 20, 1999
Trial Information
Current as of January 20, 2025
Completed
Keywords
ClinConnect Summary
Abuse of prescription opioid medications has increased dramatically in the U.S. during the past decade, as indicated by a variety of epidemiological sources. However, few studies have systematically examined the relative reinforcing effects of commonly abused opioid medications. The current inpatient study was designed to compare the effects of intravenously delivered fentanyl , oxycodone, morphine, buprenorphine and heroin in morphine-maintained heroin abusers. All of the participants received all of the drugs tested; drugs and doses were administered in non-systematic order.
Gender
ALL
Eligibility criteria
- • Inclusion Criterion
- • 1. DSM IV criteria for opioid dependence
- • 2. No major mood, psychotic, or anxiety disorder
- • 3. Physically healthy
- • 4. Able to perform study procedures
- • 5. 21-45 years of age
- • 6. Current use of i.v. heroin in amounts/frequencies
- • 7. Not seeking treatment for opioid dependence
- • Exclusion Criterion
- • 1. DSM IV criteria for dependence on drugs other
- • 2. Participants requesting treatment
- • 3. Participants on parole or probation
- • 4. Pregnancy or lactation
- • 5. Birth, miscarriage or abortion with 6 months
- • 6. Recent history of or current significant violent behavior
- • 7. Current major Axis I psychopathology, other than heroin dependence ( e.g., mood disorder with functional impairment or suicide risk, schizophrenia), which might interfere with ability to participate in the study
- • 8. Hepatitis with SGOT or SGPT \> 3 times normal
- • 9. Significant suicide risk
- • 10. Current or history of chronic pain
- • 11. Sensitivity, allergy, or contraindication to opioids
Trial Officials
Herbert Kleber, M.D.
Principal Investigator
New York State Psychiatric Institute
About New York State Psychiatric Institute
The New York State Psychiatric Institute (NYSPI) is a leading research organization dedicated to advancing the understanding and treatment of mental health disorders. Affiliated with Columbia University, NYSPI integrates clinical research with cutting-edge scientific inquiry to develop innovative therapeutic strategies and improve patient care. With a focus on a wide range of psychiatric conditions, NYSPI conducts clinical trials that aim to translate findings from laboratory research into effective interventions, enhancing the quality of life for individuals affected by mental illness. Committed to ethical research practices and collaboration, NYSPI plays a pivotal role in shaping the future of psychiatric care through rigorous scientific exploration and community engagement.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
New York, New York, United States
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials